218 related articles for article (PubMed ID: 38786424)
1. Role of TORS as De-Escalation Strategy in HPV-Related Oropharyngeal Cancer, What We Need to Know.
Molteni G; Bassani S; Arsie AE; Zampieri E; Mannelli G; Orlandi E; Bossi P; De Virgilio A
Healthcare (Basel); 2024 May; 12(10):. PubMed ID: 38786424
[TBL] [Abstract][Full Text] [Related]
2. De-intensified adjuvant (chemo)radiotherapy versus standard adjuvant chemoradiotherapy post transoral minimally invasive surgery for resectable HPV-positive oropharyngeal carcinoma.
Howard J; Dwivedi RC; Masterson L; Kothari P; Quon H; Holsinger FC
Cochrane Database Syst Rev; 2018 Dec; 12(12):CD012939. PubMed ID: 30550641
[TBL] [Abstract][Full Text] [Related]
3. 30-day morbidity and mortality after transoral robotic surgery for human papillomavirus (HPV) associated oropharyngeal squamous cell carcinoma: A retrospective analysis of two prospective adjuvant de-escalation trials (MC1273 & MC1675).
Haller TJ; Yin XL; O'Byrne TJ; Moore EJ; Ma DJ; Price KP; Patel SH; Hinni ML; Neben-Wittich MA; McGee LA; Price DL; Janus JR; Kasperbauer JK; Nagel TH; Routman DM; Lester SC; Rwigema JCM; Chintakuntlawar AV; Savvides PS; Garcia JJ; Foote RL; Van Abel KM
Oral Oncol; 2023 Feb; 137():106248. PubMed ID: 36603364
[TBL] [Abstract][Full Text] [Related]
4. Surgical clinical trials for HPV-positive oropharyngeal carcinoma.
Lin C; Sharbel DD; Topf MC
Front Oncol; 2022; 12():992348. PubMed ID: 36439459
[TBL] [Abstract][Full Text] [Related]
5. De-Escalated Adjuvant Therapy After Transoral Robotic Surgery for Human Papillomavirus-Related Oropharyngeal Carcinoma: The Sinai Robotic Surgery (SIRS) Trial.
Miles BA; Posner MR; Gupta V; Teng MS; Bakst RL; Yao M; Misiukiewicz KJ; Chai RL; Sharma S; Westra WH; Kim-Schulze S; Dayal B; Sobotka S; Sikora AG; Som PM; Genden EM
Oncologist; 2021 Jun; 26(6):504-513. PubMed ID: 33675133
[TBL] [Abstract][Full Text] [Related]
6. A Descriptive Study of Quality of Life Following Neoadjuvant Chemotherapy and Transoral Robotic Surgery for Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma.
Diaconescu A; Silver JA; Subramaniam T; Sewitch MJ; Mascarella MA; Ramirez-Garcia Luna J; Golabi N; Richardson K; Bouganim N; Forghani R; Marcin Mlynarek A; Hier MP; Sadeghi N
J Otolaryngol Head Neck Surg; 2024; 53():19160216241248670. PubMed ID: 38888957
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of transoral robotic surgery for early-stage oropharyngeal squamous cell carcinoma with low rates of adjuvant therapy: A consecutive single-institution study from 2013 to 2020.
Meldgaard Justesen M; Kronberg Jakobsen K; Fenger Carlander AL; Hjordt Holm Larsen M; Wessel I; Kiss K; Friborg J; Ibrahim Channir H; Rubek N; Grønhøj C; von Buchwald C
Oral Oncol; 2024 May; 152():106783. PubMed ID: 38569317
[TBL] [Abstract][Full Text] [Related]
8. The role of transoral robotic surgery in the management of oropharyngeal cancer.
Dias FL; Walder F; Leonhardt FD
Curr Opin Oncol; 2017 May; 29(3):166-171. PubMed ID: 28252460
[TBL] [Abstract][Full Text] [Related]
9. Early T1-T2 stage p16+ oropharyngeal tumours. Role of upfront transoral robotic surgery in de-escalation treatment strategies. A review of the current literature.
Carnevale C; Ortiz-González I; Ortiz-González A; Bodi-Blanes L; Til-Pérez G
Oral Oncol; 2021 Feb; 113():105111. PubMed ID: 33341006
[TBL] [Abstract][Full Text] [Related]
10. Locoregional Recurrence in p16-Positive Oropharyngeal Squamous Cell Carcinoma After TORS.
Carey RM; Brody RM; Shimunov D; Shinn JR; Mady LJ; Rajasekaran K; Cannady SB; Lin A; Lukens JN; Bauml JM; Cohen RB; Basu D; O'Malley BW; Weinstein GS; Newman JG
Laryngoscope; 2021 Dec; 131(12):E2865-E2873. PubMed ID: 34076275
[TBL] [Abstract][Full Text] [Related]
11. Costs of Definitive Chemoradiation, Surgery, and Adjuvant Radiation Versus De-Escalated Adjuvant Radiation per MC1273 in HPV+ Cancer of the Oropharynx.
Waddle MR; Ma DJ; Visscher SL; Borah BJ; May JM; Price KA; Moore EJ; Patel SH; Hinni ML; Chintakuntlawar AV; Garcia JJ; Graner DE; Neben-Wittich MA; Garces YI; Hallemeier CL; Price DL; Kasperbauer JL; Janus JR; Foote RL; Miller RC
Int J Radiat Oncol Biol Phys; 2021 Jun; 110(2):396-402. PubMed ID: 33359567
[TBL] [Abstract][Full Text] [Related]
12. Human papillomavirus oropharynx carcinoma: Aggressive de-escalation of adjuvant therapy.
Moore EJ; Van Abel KM; Routman DM; Lohse CM; Price KAR; Neben-Wittich M; Chintakuntlawar AV; Price DL; Kasperbauer JL; Garcia JJ; Hinni ML; Patel SH; Janus JR; Foote RL; Ma DJ
Head Neck; 2021 Jan; 43(1):229-237. PubMed ID: 32969095
[TBL] [Abstract][Full Text] [Related]
13. Do We Have Enough Evidence to Specifically Recommend Transoral Robotic Surgery in HPV-Driven Oropharyngeal Cancer? A Systematic Review.
De Virgilio A; Costantino A; Rizzo D; Crescio C; Gallus R; Spriano G; Mercante G; Festa BM; Accorona R; Pignataro L; Capaccio P; Bussu F
Pathogens; 2023 Jan; 12(2):. PubMed ID: 36839432
[No Abstract] [Full Text] [Related]
14. The Sinai Robotic Surgery Trial in HPV-related oropharyngeal squamous cell carcinoma (SIRS 2.0 trial) - study protocol for a phase II non-randomized non-inferiority trial.
Chai RL; Ferrandino RM; Barron C; Donboli K; Roof SA; Khan MN; Teng MS; Posner MR; Bakst RL; Genden EM
Front Oncol; 2022; 12():965578. PubMed ID: 36091121
[TBL] [Abstract][Full Text] [Related]
15. Minimally invasive surgery versus radiotherapy/chemoradiotherapy for small-volume primary oropharyngeal carcinoma.
Howard J; Masterson L; Dwivedi RC; Riffat F; Benson R; Jefferies S; Jani P; Tysome JR; Nutting C
Cochrane Database Syst Rev; 2016 Dec; 12(12):CD010963. PubMed ID: 27943254
[TBL] [Abstract][Full Text] [Related]
16. The Role of Transoral Robotic Surgery in the Management of HPV Negative Oropharyngeal Squamous Cell Carcinoma.
Sload R; Silver N; Jawad BA; Gross ND
Curr Oncol Rep; 2016 Sep; 18(9):53. PubMed ID: 27469262
[TBL] [Abstract][Full Text] [Related]
17. Risk of Pathologic Extranodal Extension and Other Adverse Features After Transoral Robotic Surgery in Patients With HPV-Positive Oropharynx Cancer.
Zebolsky AL; George E; Gulati A; Wai KC; Carpenter P; Van Zante A; Ha PK; Heaton CM; Ryan WR
JAMA Otolaryngol Head Neck Surg; 2021 Dec; 147(12):1080-1088. PubMed ID: 34673904
[TBL] [Abstract][Full Text] [Related]
18. The impact of transoral robotic surgery on the overall treatment of oropharyngeal cancer patients.
Smith RV; Schiff BA; Garg M; Haigentz M
Laryngoscope; 2015 Nov; 125 Suppl 10():S1-S15. PubMed ID: 26436491
[TBL] [Abstract][Full Text] [Related]
19. Trans oral robotic surgery versus definitive chemoradiotherapy for oropharyngeal cancer: 10-year institutional experience.
Meccariello G; Bianchi G; Calpona S; Parisi E; Cammaroto G; Iannella G; Sgarzani R; Montevecchi F; De Vito A; Capaccio P; Pelucchi S; Vicini C
Oral Oncol; 2020 Nov; 110():104889. PubMed ID: 32653838
[TBL] [Abstract][Full Text] [Related]
20. Differences in Functional and Survival Outcomes Between Patients Receiving Primary Surgery vs Chemoradiation Therapy for Treatment of T1-T2 Oropharyngeal Squamous Cell Carcinoma.
Amin DR; Philips R; Bertoni DG; Mastrolonardo EV; Campbell DJ; Agarwal AM; Tekumalla S; Urdang ZD; Luginbuhl AJ; Cognetti DM; Curry JM
JAMA Otolaryngol Head Neck Surg; 2023 Nov; 149(11):980-986. PubMed ID: 37422846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
